Trial Profile

Strategic Study of Dual-therapy With Darunavir/Ritonavir and Rilpivirine QD Versus Triple-therapy in Patients With Suppressed Viral Load: Virological Efficacy and Evaluation of Non-HIV Related Morbidity.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darunavir (Primary) ; Rilpivirine (Primary) ; Antiretrovirals; HIV protease inhibitors; Ritonavir
Indications HIV infections
Focus Therapeutic Use
Acronyms DUAL

11 Jan 2019 Status changed from recruiting to completed.
27 Oct 2017 Results (n=37) assessing the virological efficacy and the impact on non-HIV related morbidity of switching to a dual therapy with darunavir-ritonavir and rilpivirine at 48 weeks, presented at the 16th European AIDS Conference.
29 Mar 2016 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017, according to ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com